Literature DB >> 17687101

Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.

Nimrod Maimon1, James Brunton, Adrienne K Chan, Theodore K Marras.   

Abstract

Mycobacterium xenopi is a water-related mycobacterium with low pathogenicity in humans. Little is known about the association between anti-tumour necrosis factor (TNF)alpha and non-tuberculous mycobacterial infections. The case history is presented of fatal M xenopi infection in a patient receiving anti-TNFalpha treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17687101      PMCID： PMC2117264          DOI： 10.1136/thx.2005.056952

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  4 in total

1.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 2.  Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.

Authors:  Lisa G Criscione; E William St Clair
Journal:  Curr Opin Rheumatol       Date:  2002-05       Impact factor: 5.006

3.  Mycobacterium xenopi: innocent bystander or emerging pathogen?

Authors:  T M Jiva; H M Jacoby; L A Weymouth; D A Kaminski; A C Portmore
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

Review 4.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071
  4 in total
  8 in total

Review 1.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

Review 2.  Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Clin Rheumatol       Date:  2011-12-15       Impact factor: 2.980

3.  Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report.

Authors:  Pasquale De Nardo; Rita Bellagamba; Angela Corpolongo; Elisa Gentilotti; Fabrizio Taglietti; Silvia Rosati; Mauro Galeazzi; Gian Domenico Sebastiani; Isabella Quinti; Emanuele Nicastri
Journal:  Clin Vaccine Immunol       Date:  2013-03-06

4.  Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.

Authors:  Shunsuke Mori; Hitoshi Tokuda; Fumikazu Sakai; Takeshi Johkoh; Akio Mimori; Norihiro Nishimoto; Sadatomo Tasaka; Kazuhiro Hatta; Hidekazu Matsushima; Shunji Kaise; Atsushi Kaneko; Shigeki Makino; Seiji Minota; Takashi Yamada; Shinobu Akagawa; Atsuyuki Kurashima
Journal:  Mod Rheumatol       Date:  2011-12-30       Impact factor: 3.023

5.  Inventory study of non-tuberculous mycobacteria in the European Union.

Authors:  Marieke J van der Werf; Csaba Ködmön; Vera Katalinić-Janković; Tiina Kummik; Hanna Soini; Elvira Richter; Dimitrios Papaventsis; Enrico Tortoli; Monique Perrin; Dick van Soolingen; Manca Zolnir-Dovč; Vibeke Ostergaard Thomsen
Journal:  BMC Infect Dis       Date:  2014-02-06       Impact factor: 3.090

6.  Cellular immune responses in HIV-negative immunodeficiency with anti-interferon-γ antibodies and opportunistic intracellular microorganisms.

Authors:  Jiraprapa Wipasa; Panuwat Wongkulab; Kriangkrai Chawansuntati; Romanee Chaiwarit; Khuanchai Supparatpinyo
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

Review 7.  Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

Authors:  Kevin L Winthrop; Eric Chang; Shellie Yamashita; Michael F Iademarco; Philip A LoBue
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

8.  Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report.

Authors:  Takahiro Takazono; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Katsunori Yanagihara; Shigeru Kohno
Journal:  BMC Infect Dis       Date:  2014-02-28       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.